MarketPulse

CNS disorders

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Minerva Neurosciences to Present CNS Pipeline at Stifel Forum Ahead of Key Phase 3 Trial

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.
NERVbiopharmaceuticalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial
BenzingaBenzinga··Na

SciSparc's NeuroThera Labs to Acquire Majority Stake in Quantum Clinical Trials Pioneer

SciSparc's NeuroThera Labs acquires 54% of quantum clinical trials company CliniQuantum for $9.46M in stock plus $2.5M earn-out, closing by March 2026.
SPRCacquisitionclinical trials
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Praxis, Stock Rallies 320%

Perceptive Advisors doubles investment in Praxis Precision Medicines to $588M, now largest holding. Stock surges 320% amid FDA submissions and strong cash position.
PRAXFDA approvalinstitutional investment